-
Study aim
-
Evaluation of Riluzole efficacy on cognitive and functional outcome of severe traumatic brain injury patients
-
Design
-
This study is a double-blind trial with parallel groups in which 50 patients with traumatic brain injury are divided into two identical intervention and control groups using block randomization method.
-
Settings and conduct
-
This study is a two-blind trial in which 50 patients with severe traumatic brain injury referred to Vali Asr Hospital in Arak are admitted to the study. These people are divided into two equal groups of intervention and control using the block randomization method. In the intervention group, riluzole was administered for 2 weeks at a dose of 500 mg every 12 hours, preferably during the first 12 hours after trauma and at the first opportunity after the ability to eat by mouth. In the control group, distilled water is used instead of riluzole. Finally, The two groups are compared in terms of main outcomes.
-
Participants/Inclusion and exclusion criteria
-
inclusion criteria: Patients with severe traumatic brain injury, Impenetrable brain injury, Age over 16 years, Ability to receive medication through the mouth or nasogastric tube, Glasgow Coma Scale less than 9, Having informed consent by family members primarily to participate in the study
Non-entry criteria: Kidney and liver failure, History of severe brain injury, Unidentifiable patients and Pregnancy .
-
Intervention groups
-
Intervention group: The treatment protocol included administration of the drug (riluzole) for 2 weeks, at a dose of 500 mg every 12 hours, preferably during the first 12 hours after trauma and at the first opportunity after the ability to eat by mouth. Control group: Distilled water will be prescribed instead of riluzole
-
Main outcome variables
-
Glasgow Coma Scale, 4 scores, Karnovsky performance status, Glasgow outcome scale, Mini Mental State Test, Disability Rating Scale